This shift in the balance between ACE and ACE-2, in favor of ACE, can result in increased angiotensin II production and activation of the RAAS, leading to the release of proinflammatory cytokines and contributing to the development of cardiovascular and renal complications in COVID-19. Here, ACE is linked to COVID-19.